Companies view Sunshine differently

Share this article:
Pfizer
Pfizer

A report by PMLive indicates that pharmaceutical companies have distinct views on what the Sunshine Act requires.

According to a presentation made at the International Society for Medical Publications Professionals, PMLive noted, for example, that Pfizer and AstraZeneca report payments for medical writing. The companies said they report the payments because the publications represent value for the company and author.

Shire's publications director Antonia Panayi, though, said her company does not consider these publications reportable because the value is limited to pharma, as opposed to being beneficial for professionals.

Panayi said the value is limited to “what has already been paid as part of their contractual agreement for the trial,” and that author “kudos” for publication would be difficult to quantify.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.